According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Weight-loss drug stocks were catapulted into the spotlight in 2024, creating a lucrative, groundbreaking, and high-stakes ...

A new quick-and-easy nasal swab test for kids can diagnose the specific immune system drivers behind their asthma, ...

Encouraging primary care physicians to screen patients for physical inactivity with a simple questionnaire can help identify ...

Kennedy Jr., President-elect Donald Trump’s nominee to head the US Department of Health and Human Services, who has expressed reservations about the pharma industry — and its new wonder drug category.

After years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller ... potential as a non-opioid painkiller. Lilly's Zepbound has become the first drug approved ...

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

In New Orleans, Celebration Is Followed by Terror in the French Quarter The attack left 15 dead and about three dozen injured. The authorities described it as an act ...